Inozyme Pharma (INZY) Short Interest Ratio & Short Volume $3.83 -0.17 (-4.25%) (As of 02:44 PM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Inozyme Pharma Short Interest DataInozyme Pharma (INZY) has a short interest of 3.23 million shares, representing 7.40% of the float (the number of shares available for trading by the public). This marks a 0.62% increase in short interest from the previous month. The short interest ratio (days to cover) is 12.3, indicating that it would take 12.3 days of the average trading volume of 416,053 shares to cover all short positions.Current Short Interest3,230,000 sharesPrevious Short Interest3,210,000 sharesChange Vs. Previous Month+0.62%Dollar Volume Sold Short$13.86 millionShort Interest Ratio12.3 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares64,240,000 sharesFloat Size43,650,000 sharesShort Percent of Float7.40%Today's Trading Volume119,679 sharesAverage Trading Volume416,053 sharesToday's Volume Vs. Average29% Short Selling Inozyme Pharma? Sign up to receive the latest short interest report for Inozyme Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartINZY Short Interest Over TimeINZY Days to Cover Over TimeINZY Percentage of Float Shorted Over Time Ad True Gold RepublicCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. Click here now to get your free 'Protect Your Wealth' Guide. Inozyme Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/20243,230,000 shares $13.86 million +0.6%7.4%12.3 $4.29 10/15/20243,210,000 shares $17.24 million -12.3%7.5%12.7 $5.37 9/30/20243,660,000 shares $19.14 million -6.9%8.6%14.1 $5.23 9/15/20243,930,000 shares $23.58 million -1.3%9.2%13.5 $6.00 8/31/20243,980,000 shares $22.05 million +0.5%9.4%13.2 $5.54 8/15/20243,960,000 shares $18.57 million -4.8%9.4%12.3 $4.69 Get the Latest News and Ratings for INZY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter. 7/31/20244,160,000 shares $24.13 million -2.4%9.9%13.3 $5.80 7/15/20244,260,000 shares $23.26 million +3.2%10.2%11.5 $5.46 6/30/20244,130,000 shares $18.42 million +51.3%9.9%8.8 $4.46 6/15/20242,730,000 shares $12.94 million +0.4%6.6%4.8 $4.74 5/31/20242,720,000 shares $13.11 million +1.1%6.5%4.5 $4.82 5/15/20242,690,000 shares $12.56 million -20.7%6.5%4.1 $4.67 4/30/20243,390,000 shares $14.95 million +7.6%8.2%5 $4.41 4/15/20243,150,000 shares $14.84 million +22.1%7.7%4.7 $4.71 3/31/20242,580,000 shares $19.76 million +8.4%6.3%4.2 $7.66 3/15/20242,380,000 shares $14.02 million +2.6%5.8%4.6 $5.89 2/29/20242,320,000 shares $14.76 million -3.3%5.6%4.8 $6.36 2/15/20242,400,000 shares $13.70 million -16.4%5.8%5.4 $5.71 1/31/20242,870,000 shares $15.79 million +4.7%6.8%6.9 $5.50 1/15/20242,740,000 shares $11.54 million -10.8%6.5%6.7 $4.21 12/31/20233,070,000 shares $13.08 million +91.9%7.2%7.6 $4.26 12/15/20231,600,000 shares $6.43 million -28.6%3.8%3.7 $4.02 11/30/20232,240,000 shares $8.62 million -0.4%5.3%4.5 $3.85 11/15/20232,250,000 shares $7.20 million +8.2%5.3%4.2 $3.20 10/31/20232,080,000 shares $6.18 million -15.5%4.7%3.6 $2.97 10/15/20232,460,000 shares $8.35 million +6.5%5.5%3.7 $3.40 9/30/20232,310,000 shares $9.70 million +12.7%5.2%3.3 $4.20 9/15/20232,050,000 shares $8.82 million +21.3%4.6%3 $4.30 8/31/20231,690,000 shares $8.28 million -17.2%4.5%2.6 $4.90 8/15/20232,040,000 shares $9.83 million +11.5%5.4%3.3 $4.82 7/31/20231,830,000 shares $9.33 million +7.7%4.0%2.8 $5.10 7/15/20231,700,000 shares $10.35 million +37.1%4.9%3.1 $6.09 6/30/20231,240,000 shares $6.91 million +248.1%3.5%2 $5.57 6/15/2023356,200 shares $2.07 million +24.9%1.0%0.5 $5.81 5/31/2023285,100 shares $1.71 million -53.0%0.8%0.4 $5.99 5/15/2023606,300 shares $3.93 million No Change1.7%0.7 $6.49 10/31/2022166,500 shares $293,040.00 -4.8%N/A2.3 $1.76 10/15/2022174,800 shares $457,976.00 -4.4%N/A2.9 $2.62 9/30/2022182,900 shares $490,172.00 No ChangeN/A2.4 $2.68 9/15/2022182,900 shares $610,886.00 -7.6%0.8%1.5 $3.34Amazon's $150B Data Center Bet—What It Means for Uranium Investors (Ad)Amazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With demand for electricity skyrocketing from data centers, AI, and emerging tech, Amazon recognizes nuclear power as the only viable solution to meet its needs sustainably and at scale. But here's the critical catch: nuclear power requires uranium, and the global supply is struggling to keep up. Read More to Learn How You Can Position Yourself for the Next Uranium Boom 8/31/2022197,900 shares $593,700.00 -25.9%0.9%1.2 $3.00 8/15/2022267,000 shares $1.00 million -18.8%1.2%1.5 $3.76 7/31/2022328,800 shares $1.21 million -26.3%N/A1.7 $3.69 7/15/2022446,200 shares $2.23 million -47.1%N/A1.8 $5.00 6/30/2022842,900 shares $4.02 million -2.5%N/A2.8 $4.77 6/15/2022864,400 shares $4.02 million +0.3%N/A2.8 $4.65 5/31/2022861,600 shares $3.18 million +13.8%N/A3.5 $3.69 5/15/2022757,200 shares $3.20 million -13.6%N/A3.4 $4.23 4/30/2022876,200 shares $3.46 million +118.3%N/A4.2 $3.95 4/15/2022401,300 shares $1.71 million +23.5%1.7%2.3 $4.26 3/31/2022325,000 shares $1.33 million +12.2%N/A3.7 $4.09 3/15/2022289,700 shares $1.17 million -3.9%2.1%4.4 $4.03 2/28/2022301,300 shares $1.74 million +9.7%2.2%4.5 $5.77 2/15/2022274,700 shares $1.95 million +5.2%2.4%4.3 $7.10 1/31/2022261,200 shares $1.74 million +57.7%2.2%4.6 $6.68 1/15/2022165,600 shares $1.12 million +8.2%N/A3.1 $6.74 12/31/2021153,000 shares $1.04 million -13.6%1.3%2.9 $6.82 12/15/2021177,000 shares $987,660.00 -3.2%1.5%2.8 $5.58 11/30/2021182,800 shares $1.45 million +4.1%1.6%2.4 $7.94 11/15/2021175,600 shares $1.76 million -7.1%1.5%2.1 $10.00 10/29/2021189,100 shares $1.77 million -3.2%1.7%2.3 $9.34 10/15/2021195,400 shares $1.81 million -14.2%1.8%2.2 $9.25 9/30/2021227,800 shares $2.64 million +11.5%2.1%2.5 $11.59 9/15/2021204,300 shares $2.56 million -43.5%1.9%2.4 $12.55 8/31/2021361,500 shares $5.57 million -5.9%3.3%5.2 $15.42 8/13/2021384,100 shares $6.10 million +3.4%3.5%6.3 $15.88 7/30/2021371,400 shares $6.23 million +32.0%3.4%5.9 $16.77 7/15/2021281,300 shares $5.12 million -78.4%2.8%4.8 $18.19 6/30/20211,300,000 shares $22.15 million +26.2%12.7%24.2 $17.04 6/15/20211,030,000 shares $17.64 million +15.4%10.1%21.5 $17.13 5/28/2021892,200 shares $14.60 million +2.4%8.7%19.7 $16.36 5/14/2021871,000 shares $13.23 million -39.5%8.5%18.3 $15.19 4/30/20211,440,000 shares $26.40 million +0.7%14.1%27.8 $18.33 4/15/20211,430,000 shares $27.01 million +8.3%N/A22.9 $18.89 3/31/20211,320,000 shares $24.20 million +20.0%16.3%20.6 $18.33 3/15/20211,100,000 shares $23.38 million No Change14.9%16.4 $21.25 2/26/20211,100,000 shares $22.98 million +8.9%14.9%18.6 $20.89 2/12/20211,010,000 shares $20.16 million +85.0%13.7%17.7 $19.96 1/29/2021546,000 shares $12.49 million +1.8%7.4%9.8 $22.88 1/15/2021536,300 shares $14.19 million No Change7.7%13.5 $26.45 INZY Short Interest - Frequently Asked Questions What is Inozyme Pharma's current short interest? Short interest is the volume of Inozyme Pharma shares that have been sold short but have not yet been closed out or covered. As of October 31st, investors have sold 3,230,000 shares of INZY short. 7.40% of Inozyme Pharma's shares are currently sold short. Learn More on Inozyme Pharma's current short interest. What is a good short interest ratio for Inozyme Pharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. INZY shares currently have a short interest ratio of 12.0. Learn More on Inozyme Pharma's short interest ratio. What is a good short interest percentage for Inozyme Pharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.40% of Inozyme Pharma's floating shares are currently sold short. Is Inozyme Pharma's short interest increasing or decreasing? Inozyme Pharma saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 3,230,000 shares, an increase of 0.6% from the previous total of 3,210,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Inozyme Pharma's float size? Inozyme Pharma currently has issued a total of 64,240,000 shares. Some of Inozyme Pharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Inozyme Pharma currently has a public float of 43,650,000 shares. How does Inozyme Pharma's short interest compare to its competitors? 7.40% of Inozyme Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Inozyme Pharma: Foghorn Therapeutics Inc. (3.93%), Eagle Pharmaceuticals, Inc. (2.90%), Mesoblast Limited (1.22%), CARGO Therapeutics, Inc. (17.43%), IGM Biosciences, Inc. (16.29%), Cullinan Therapeutics, Inc. (23.03%), Phibro Animal Health Co. (2.03%), 89bio, Inc. (5.47%), Prothena Co. plc (14.00%), Pliant Therapeutics, Inc. (11.87%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Inozyme Pharma stock? Short selling INZY is an investing strategy that aims to generate trading profit from Inozyme Pharma as its price is falling. INZY shares are trading down $0.17 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Inozyme Pharma? A short squeeze for Inozyme Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of INZY, which in turn drives the price of the stock up even further. How often is Inozyme Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including INZY, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies FHTX Short Interest Data EGRX Short Interest Data MESO Short Interest Data CRGX Short Interest Data IGMS Short Interest Data CGEM Short Interest Data PAHC Short Interest Data ETNB Short Interest Data PRTA Short Interest Data PLRX Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:INZY) was last updated on 11/12/2024 by MarketBeat.com Staff From Our PartnersAmazon's $150B Data Center Bet—What It Means for Uranium InvestorsAmazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With dem...The Bull Report | SponsoredOptions Trading on Bitcoin?SEC Approves Crypto Options Trading Select altcoins poised for RAPID growth by early 2025… Crypto 101 Media | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | SponsoredCritical warning from the mountains of CarolinaNvidia CEO Jensen Huang says Big Tech will spend over $1 trillion on data centers. And that still might not...Weiss Ratings | SponsoredCrypto’s FINAL Wealth MomentBitcoin’s final bull market is here. If you missed out on the gains in 2017, or 2021… 2025 stands to be jus...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inozyme Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
